Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
517 Splenic tumor-reactive CD8+ T cells are endowed with a unique potential for expansion and are the dominant source of systemic anti-tumor immunity after ICB therapy
Compose a Response to This Article
Other responses
No responses have been published for this article.